340B
-
AMP is WAC — 04/10/26
Read more: AMP is WAC — 04/10/26Dam. What a few weeks. I Whistlered while I worked, but the avalanche of news has been hard to keep up with. (I mean, I found it funny.) If you’re interested, I’m hosting a free webinar on April 23 at 12 EST on Most Favored Nation. Quick 30-minute dive. Link to register is here: https://us06web.zoom.us/webinar/register/WN_iPlbMuS5RmeGSbcB8RSi-g…
-
340B, Affordable Care Act, Alzheimer’s, Biosimilars, Cell and Gene, CMMI, FDA, Inflation Reduction Act, Medicare Part D, ObesityAMP is WAC — 03/13/26
Read more: AMP is WAC — 03/13/26The Bigger They Are, the Faster They Grow. A new white paper from Health Capital Group, sponsored by Johnson & Johnson, analyzed HRSA’s OPAIS database from 2017 through 2023 and found something many observers of the 340B program have suspected for years; size is the dominant variable. Hospitals in the top quartile by bed size…
-
340B, Caught my eye, Drug Prices, Inflation Reduction Act, Medicaid, Medicare Part D, Pharmacy Benefit ManagersAMP is WAC — 3/6/26
Read more: AMP is WAC — 3/6/26Can you ever feel sad looking at photo of a chimp wearing clothes? Maybe it will make the latest policy news go down just a little smoother. 340B’s Split Screen. February 26 brought two developments in the 340B contract pharmacy fight. They pointed in opposite directions. First, a judge in the Middle District of Tennessee…
-
340B, Biosimilars, Caught my eye, DTC, Employers, FDA, Obesity, Reference Pricing, State-based Reform, ValueAMP is WAC — 2/20/26
Read more: AMP is WAC — 2/20/26We have some new folks around these parts so quick intro. I’m Jennifer Snow. I’ve spent 25 years inside the U.S. pharmaceutical policy world, not watching it from the outside, but sitting in the meetings, reading the rules, and translating what they actually mean for the people whose drugs are on the line. I’m not…
-
340B, Affordable Care Act, Biosimilars, Caught my eye, Drug Prices, Inflation Reduction Act, Insulin, Medicare Negotiation, Medicare Part D, Pharmacy Benefit Managers, State-based Reform, Utilization ManagementAMP is WAC — 2/13/26
Read more: AMP is WAC — 2/13/26I chuckled during the E&C hearing when members were questioning the panelists about the pharmaceutical deals with the Administration. As if these are the people they should be asking. Make a left, make right, go down about a mile – there’s a big white house. Maybe they can help you there. Parallels Between 340B and…
-
340B, Caught my eye, CMMI, Drug Prices, FDA, Healthcare Costs, Inflation Reduction Act, Medicare Advantage, Medicare Negotiation, Medicare Part D, Orphan Drugs, Pharmacy Benefit Managers, Reference Pricing, ValueAMP is WAC — 1/16/26
Read more: AMP is WAC — 1/16/26In case you thought I’d leaving you hanging, today’s newsletter has a summary on GLOBE. Sphere it below? Calling it a Plan would be GENEROUS, but that’s a Whole Other Thing. On Thursday, the White House released a fact sheet urging Congress to enact President Trump’s “Great Healthcare Plan,” pitching it as a cost-cutting package…
-
340B, Caught my eye, CMMI, Drug Prices, FDA, Generics, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Medicare Transaction Facilitator, Medicare Transaction Facilitator, Obesity, Reference PricingAMP is WAC — 1/9/26
Read more: AMP is WAC — 1/9/26Something is bugging me this week. Okay, lots of things are bugging me this week, but the one that is relevant to this newsletter is the STAT News headline that implied it is awesome to be a pharmaceutical executive in 2026. This week, there were reports of more than 25,000 layoffs in pharma last year.…
-
340B, Affordable Care Act, Caught my eye, CMMI, Drug Prices, Healthcare Costs, ICER, Medicare Part D, Pharmacy Benefit Managers, Reference Pricing, State-based Reform, Utilization ManagementAMP is WAC — 12/19/25
Read more: AMP is WAC — 12/19/25Today we’re expecting to hear more about manufacturer Most Favored Nation (MFN) agreements and (if you trust the rumors) maybe more about the MFN demos – the Global Benchmark for Efficient Drug Pricing (GLOBE) Model and the Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model. I wasn’t planning on publishing the next two weeks,…
-
340B, Alzheimer’s, Caught my eye, FDA, Healthcare Costs, Inflation Reduction Act, Medicare Negotiation, Preventative, Reference Pricing, ValueAMP is WAC — 12/12/25
Read more: AMP is WAC — 12/12/25Much of this week felt like playing catch-up from past weeks. Good timing because rumors are swirling about Most Favored Nation (MFN) demonstration releases for late next week. Comment letter fun during the holidays! For those of you who are new to these parts… welcome! I’m a health policy strategist focused on pharmaceuticals. My goal…
-
340B, Affordable Care Act, Caught my eye, CMMI, Drug Prices, Home Health, Inflation Reduction Act, Medicare Advantage, Medicare Negotiation, Medicare Part D, Preventative, Reference Pricing, TariffsAMP is WAC — 12/5/25
Read more: AMP is WAC — 12/5/25It is the kind of month where I walk around with a legal pad to capture all the random thoughts floating around my head. Which is how “figure out gift baking (scones? Levain cookies?)” ends up next to “Look at MedPAC agenda.” There are no dull moments around here. While I’m on the topic. MedPAC…
Latest news
- AMP is WAC — 04/24/26
- AMP is WAC — 04/10/26
- AMP is WAC — 03/27/26
- AMP is WAC — 03/20/26
- AMP is WAC — 03/13/26
Categories
- 340B (64)
- Affordable Care Act (23)
- Alzheimer's (11)
- Biosimilars (33)
- Caught my eye (102)
- Cell and Gene (8)
- Chevron Deference (2)
- CMMI (29)
- Copay Accumulators (7)
- COVID (3)
- Drug Prices (58)
- Drug shortages (15)
- DTC (9)
- Employers (20)
- FDA (8)
- Generics (13)
- Health Equity (4)
- Healthcare Costs (41)
- Home Health (1)
- ICER (12)
- Importation (5)
- Inflation Reduction Act (69)
- Insulin (7)
- IP (3)
- Long term care (1)
- Medicaid (24)
- Medicare Advantage (27)
- Medicare Negotiation (68)
- Medicare Part D (78)
- Medicare Transaction Facilitator (5)
- Medicare Transaction Facilitator (12)
- Obesity (28)
- On the Horizon (1)
- Orphan Drugs (8)
- Pharmacy Benefit Managers (49)
- Preventative (5)
- Reference Pricing (26)
- State-based Reform (32)
- Supply Chain (8)
- Tariffs (2)
- Uncategorized (9)
- Utilization Management (14)
- Vaccines (10)
- Value (18)